Quick answer: Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated peptide that was first isolated from calf thymus extracts and corresponds to the amino-terminal portion of the larger precursor protein prothymosin alpha. In the preclinical literature it is studied for its effects on toll-like receptor (TLR) signalling in dendritic cells and for questions about T-cell maturation and immune regulation. It is a laboratory research compound only. This explainer covers the name and structure, how it differs from thymosin beta-4 and TB-500, what cell and animal-model papers report, and what to check on a certificate of analysis.
Where the name thymosin alpha-1 comes from
The thymosins are a loose family of peptides named for the thymus, the organ where T cells mature. In the 1960s and 1970s, Allan Goldstein and colleagues prepared a crude calf-thymus extract called thymosin fraction 5 and then separated it into its component peptides. Two of the best-known fractions were named with Greek letters: alpha and beta. The name therefore reflects the order in which fractions were purified, not a shared structure.
Thymosin alpha-1 was purified and sequenced in the late 1970s. Papers in the Journal of Biological Chemistry in 1979 described its isolation, its biological activities in assay systems and its full amino acid sequence. Later work showed that it is not a separate gene product, but a fragment cut from the front end of prothymosin alpha, a longer protein found in the nucleus of many cell types.
Structure in plain terms
The peptide has 28 residues, and its amino terminus carries an acetyl group, a small chemical cap that is part of the natural form. The sequence is rich in acidic residues (aspartate and glutamate), which gives the molecule a strongly negative charge at neutral pH and a molecular weight of roughly 3,100 g/mol. At that size it is a mid-length peptide: far longer than a tetrapeptide and much shorter than a protein, so synthesis requires many coupling steps and the final product can contain closely related truncated or deletion sequences. That is one reason documentation matters, covered below.
Natural thymosin alpha-1 appears to be largely unstructured in water, but it has been reported to adopt a helical conformation in less polar environments, such as in the presence of membrane-mimicking solvents. Researchers sometimes cite this property when they discuss how a flexible peptide might engage a receptor surface.
What the preclinical literature examines
Everything below is cell-culture or animal-model research. None of it is a statement about use in people.
TLR signalling in dendritic cells. A 2004 paper in Blood reported that thymosin alpha-1 activated mouse dendritic cells through MyD88-dependent toll-like receptor signalling (the 2006 follow-up below points to TLR9), and that this shaped antifungal Th1 responses in a mouse model of aspergillosis. The work is a central citation in the field because it moved the discussion from general immune activity to a defined signalling pathway.
Tryptophan catabolism and tolerance. A 2006 follow-up in Blood described activation of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase in dendritic cells exposed to the peptide, and framed the results as a balance between inflammatory and regulatory signals rather than simple stimulation.
Cystic fibrosis mouse models. A 2017 paper in Nature Medicine used mouse models and cells to examine whether the peptide influenced inflammation, and reported effects on CFTR-related readouts in those experimental systems. It is preclinical work, it was later followed by two erratum notices in the same journal in 2018, and it does not establish effects in any person.
Historical and review context. Overviews published in the Annals of the New York Academy of Sciences summarize the path from thymic extract to a defined 28-residue peptide, and they describe the T-cell maturation and cytokine-production assays used over decades. Reading a review first and the primary papers second is a sensible order.
How thymosin alpha-1 differs from thymosin beta-4 and TB-500
The two share a family label and little else. Thymosin beta-4 is a 43-residue protein-like peptide that binds monomeric actin and is abundant inside many cells, so its research context is cytoskeleton dynamics and cell migration. Thymosin alpha-1 is shorter, acidic, derived from prothymosin alpha, and studied around immune-cell signalling. TB-500 is a name used for a synthetic fragment related to thymosin beta-4, so it belongs with the beta line of work. For a side-by-side of those two, see TB-500 vs. thymosin beta-4, and for the synthetic fragment itself see TB-500 research overview.
Thymosin family members at a glance
The table below lists basic descriptors only, so you can tell the molecules apart on a catalog or a paper.
| Compound | Length | Origin | Typical research context |
|---|---|---|---|
| Thymosin alpha-1 | 28 residues, N-terminally acetylated, about 3.1 kDa | N-terminal fragment of prothymosin alpha; first purified from thymic extract | TLR signalling, dendritic-cell and T-cell models |
| Prothymosin alpha | About 110 residues | Larger nuclear precursor protein | Cell proliferation and chromatin-related models |
| Thymosin beta-4 | 43 residues, about 4.9 kDa | Abundant actin-binding protein found in many cell types | Actin dynamics, cell migration and tissue-repair models |
| TB-500 | Short synthetic fragment related to thymosin beta-4 | Laboratory synthesis | Cell migration and actin-related models; see TB-500 |
Regulatory context
A synthetic form of the peptide, thymalfasin, is a regulated drug in some countries but not in the United States, and that status has no bearing on products sold by V8 Peptides, which are for laboratory research only.
Handling the lyophilized powder
Thymosin alpha-1 is supplied as a freeze-dried powder. Keep sealed vials cold, dry and protected from light, avoid repeated warming and cooling, and log the date a vial is first opened. Let a cold vial reach room temperature before opening to limit condensation. Acidic peptides of this length can be sensitive to repeated freeze-thaw cycles once in solution, so plan experiments so that you open a vial as few times as possible. For general guidance read storing research peptides. To work out a stock solution for an in-vitro assay, use the reconstitution calculator.
Availability from V8 Peptides
A 10 mg vial of thymosin alpha-1 is coming soon to the V8 catalog, and its page will be at /products/thymosin-alpha-1. Products from V8 Peptides are sold for laboratory research use only, and certificates of analysis are published on the COA page for tested lots. You can browse current listings in the shop.
Common misunderstandings
“Thymosin alpha-1 and beta-4 are the same thing.” They are different peptides with different lengths, origins and research contexts.
“It is a hormone made by the thymus only.” The sequence comes from prothymosin alpha, which is expressed widely, so the thymic label is largely historical.
“Cell and mouse data predict outcomes in other species.” They do not, and this article makes no such claim.
“Any purity percentage is good enough.” At 28 residues, a single headline number can hide related impurities, so read the chromatogram.
What to check on a COA
Because a 28-residue peptide takes many synthesis steps, a certificate of analysis is more informative here than for a short sequence. Look for the following.
HPLC purity with the chromatogram, not only a percentage. Check whether shoulder peaks near the main peak are visible and how they were integrated. Understanding HPLC purity explains the numbers.
Identity confirmation. Ask which method confirms that the measured molecular weight matches the expected value of roughly 3,100 g/mol, and read the result in the report. Note that the acetyl cap changes the mass compared with an uncapped sequence.
Lot reference and date that match the vial, plus the name of the testing laboratory.
Stated fill amount and whether it means total powder or net peptide, since counter-ions add mass.
Walk through each section with how to read a COA.
Frequently asked questions
What is thymosin alpha-1?
A 28-amino-acid, N-terminally acetylated peptide corresponding to the front end of prothymosin alpha, first isolated from thymic extract.
How big is thymosin alpha-1?
Roughly 3,100 g/mol, with 28 residues.
Where does it come from?
Natively it is cut from prothymosin alpha. Laboratory material is made by chemical peptide synthesis.
How does it differ from thymosin beta-4?
Thymosin beta-4 has 43 residues and binds actin, while thymosin alpha-1 has 28 residues and is studied around immune-cell signalling. They are unrelated in sequence.
Is TB-500 the same as thymosin alpha-1?
No. TB-500 is a synthetic fragment related to thymosin beta-4, which belongs to the beta line of research.
What kind of studies mention it?
Cell-culture and mouse studies on TLR signalling in dendritic cells, tryptophan catabolism, T-cell maturation and inflammation-related readouts.
Is it a regulated drug anywhere?
A synthetic form, thymalfasin, is a regulated drug in some countries. That does not apply to products sold by V8 Peptides.
Is it approved in the United States?
No. V8 Peptides sells its products for laboratory research use only, not for human or animal consumption.
What should I look for on a COA?
An HPLC chromatogram, an identity method that confirms the expected mass, a lot reference matching your vial, a test date and a named laboratory.
How is lyophilized thymosin alpha-1 stored?
Sealed, cold, dry and protected from light, with temperature cycling avoided and the opening date recorded.
References
- Low TL, Goldstein AL. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254(3):981-986. PMID: 216684.
- Low TL, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. J Biol Chem. 1979;254(3):987-995. PMID: 762108.
- Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-4239. PMID: 14982877.
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. PMID: 16741252.
- Romani L, Oikonomou V, Moretti S, et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017;23(5):590-600. PMID: 28394330.
- Romani L, Moretti S, Fallarino F, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326-338. PMID: 17495242.
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. PMID: 17567941.
All V8 Peptides products are sold for laboratory research use only. They are not drugs, foods, or cosmetics and are not intended for human or animal consumption.
